QR Kodea

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of puta...

Deskribapen osoa

Gorde:
Egile Nagusiak: O. Kirakosyan, M. Reimann, A.B. Andersen, A. Bjarnason, Á. Bakos, A.M. Dyrhol-Riise, A.M. McLaughlin, C. Nita, D. Pieridou, D. Chesov, E.V. Davidavičienė, G. Günther, H. Atshemyan, I. Muylle, I. Solovic, J. Bruchfeld, K. Manika, L. Kuksa, L.R. Codecasa, M. Stosic, M. Skowroński, M.J. Makek, M. Fréchet Jachym, M. Knappik, M. Santin, N. Yatskevich, O. Konstantynovska, O. Akkerman, P. Svetina, P. Viiklepp, R. Duarte, S. Zeynel, T. Togonidze, T. Vasankari, V. Parris, Ş. Özkara, C. Lange, T.T. Brehm
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: International Union Against Tuberculosis and Lung Disease (The Union) 2025-02-01
Saila:IJTLD Open
Gaiak:
hepatotoxicity
drug-induced liver injury
hepatitis
silibinin
ursodeoxycholic acid
Sarrera elektronikoa:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak